Actinogen Medical Limited (AU:ACW) has released an update.
Actinogen Medical’s CEO Dr. Steven Gourlay highlighted the company’s promising drug Xanamem at the Pitt Street Research Conference, which aims to treat depression and Alzheimer’s disease by controlling brain cortisol. With positive results from recent clinical trials, the company looks forward to the potential of Xanamem as it enters late-phase testing. This innovative treatment addresses a significant unmet need for new therapies in neurological and psychiatric diseases.
For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.
